Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Fibrocell and Hefei Meifu Announce JV

publication date: Nov 5, 2010
Fibrocell Science, Inc. will set up a joint venture with Hefei Meifu Bio-Tech Limited, centered on developing its autologous fibroblast therapies for aesthetic use in Asia, excluding Japan. Fibrocell will contribute its fibroblast IP, clinical data and manufacturing processes. Meifu will build a manufacturing facility in Hefei and be responsible for commercialization and marketing. Further financial details were not disclosed. More details....

Stock Symbol: (OTCBB: FCSC)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital